Keynote 1 | Sep 7, 16:15 - 16:45 CEST (10:15 NYC, 22:15 SGP)
Lawrence L. Wald, Ph.D., Martinos Center for Biomedical Imaging, Harvard, USA
Lawrence L. Wald, Ph.D., is currently a Professor of Radiology at Harvard Medical School, Affiliated Faculty of the Harvard-MIT Division Health Sciences Technology and Sara & Charles Fabrikant Research Scholar at the Massachusetts General Hospital. He received a BA in Physics at Rice University, and a Ph.D. in Physics from the University of California at Berkeley in 1992 under the direction of Prof. E.L. Hahn with a thesis related to optical detection of NMR. He obtained further (postdoctoral) training in Physics at Berkeley and then in Radiology and MRI at the University of California at San Francisco (UCSF). He began his academic career as an Instructor at the Harvard Medical School and since 1998 has been at the Massachusetts General Hospital Dept. of Radiology A.A. Martinos Center for Biomedical Imaging.His recent work focuses on improving methods for functional brain imaging. He has worked on the benefits and challenges of highly parallel MRI and its application to faster image encoding and parallel excitation and ultra-high field MRI (7 Tesla) methodology, and also improved method for studying the Human Connectome and portable MRI technology. Recent work has included studying the feasibility of functional brain imaging with Magnetic Particle Imaging (MPI) using Cerebral Blood Volume (CBV) contrast and analysis of the instrumentation needed for fMPI of humans. This has also led to extending understanding of Peripheral Nerve Stimulation (PNS) in human MPI and MRI using electromagnetic body models with full nerve atlases and a detailed neuro-dynamic model to predict magneto-stimulation thresholds. Dr. Wald is a Fellow of the International Society of Magnetic Resonance (ISMRM) and the College of Fellows of the American Institute for Medical and Biologial Engineering (AIMBE).
Keynote 2 | Sep 8, 16:30 - 17:00 CEST (10:30 NYC, 22:30 SGP)
Jochen Franke, Product Manager Magnetic Particle Imaging, System Engineering & Integration
Preclinical imaging plays an important role in the understanding of biological processes in both healthy and diseased states and of responses to pharmacological, physiological or environmental challenges. Especially in demanding times like the current COVID-19 pandemic, a comprehensive understanding of biological systems is crucial. The use of state-of-the-art analytical technologies can significantly advance clinical diagnosis and therapy routines.
Bruker BioSpin is a renowned provider of state-of-the-art imaging technologies, ranging from Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) to its youngest imaging technology, Magnetic Particle Imaging (MPI). With our mission to develop each imaging technology to its best, Bruker drives innovation in new methodologies and solutions for scientists enabling ground-braking discoveries. Our instruments allow for important assessments of healthy and diseased mechanisms at organ, tissue, cell, and molecular levels. Preclinical imaging is also central to evaluate the effectiveness and safety of new treatments and describing drug distribution patterns before clinical usage. That is why Bruker continues to invest in innovation and new technologies, especially in the current demanding times to support the fight against the COVID-19 pandemic.
For head-to-toe investigations in your research, we seamlessly combine different imaging technologies in multimodal, easy-to-use instruments. Best-in-class hardware and software packages offer optimized workflows from animal handling to morphological and functional data acquisition to image reconstruction and post-processing steps. This includes quantification and visualization tools for various biomedical imaging applications.
With the help of numerous collaborations with leading research centers and our dynamic development teams, Bruker is investing in the advancement of Magnetic Particle Imaging in the preclinical area, paving the translational way to clinical perspectives. The use of nanomaterials and their specific response to external magnetic fields is not only crucial for molecular imaging, but opens the door to the development of novel theranostic strategies, which in turn can improve patient outcomes and save lives.
Be inspired by the recent achievements of our outstanding MPI community in the life sciences and join us to take molecular imaging to the next level.